Extended Data Fig. 5: Association of frequently mutated genes with clinical outcome in IMbrave 150.
Forest plots of progression-free survival (PFS) (a) or overall survival (OS) (b) in IMbrave150 patients (n = 130) either possessing (Mut) or not possessing (WT) mutations in the indicated gene, for the six genes observed to be mutated in > 10% of patients in the study. Mutations are defined as somatic short variants that are either recurrent in cancer (known) or disrupt tumor suppressor genes or are in known hotspot regions (likely) by Foundation Medicine criteria. Statistics are calculated by a two-sided Cox model stratified with variables as stated elsewhere. Points and whiskers in the plot are hazard ratio and confidence interval, respectively. Atezo, atezolizumab; Bev, bevacizumab; NA, not achieved.
